JP6976946B2 - 生理活性の強い、ｕｒａｔ１のインヒビターを含む医薬組成物 - Google Patents

生理活性の強い、ｕｒａｔ１のインヒビターを含む医薬組成物 Download PDF

Info

Publication number
JP6976946B2
JP6976946B2 JP2018529601A JP2018529601A JP6976946B2 JP 6976946 B2 JP6976946 B2 JP 6976946B2 JP 2018529601 A JP2018529601 A JP 2018529601A JP 2018529601 A JP2018529601 A JP 2018529601A JP 6976946 B2 JP6976946 B2 JP 6976946B2
Authority
JP
Japan
Prior art keywords
release
pharmaceutical composition
cellulose
thio
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018529601A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019501895A (ja
Inventor
ジョアン・ライランド・ウェイクマン
コリン・ローリングス
シャ・リウ
ジェリー・バーク
クリスティアン・ヴォン・コルスヴァント
クリステル・タンネルグレン
ヨハン・ヤルトスタム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Ardea Biociences Inc
Original Assignee
AstraZeneca AB
Ardea Biociences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57517882&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6976946(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca AB, Ardea Biociences Inc filed Critical AstraZeneca AB
Publication of JP2019501895A publication Critical patent/JP2019501895A/ja
Priority to JP2021182955A priority Critical patent/JP2022033758A/ja
Application granted granted Critical
Publication of JP6976946B2 publication Critical patent/JP6976946B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2018529601A 2015-12-08 2016-12-07 生理活性の強い、ｕｒａｔ１のインヒビターを含む医薬組成物 Expired - Fee Related JP6976946B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021182955A JP2022033758A (ja) 2015-12-08 2021-11-10 生理活性の強い、ｕｒａｔ１のインヒビターを含む医薬組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562264792P 2015-12-08 2015-12-08
US62/264,792 2015-12-08
PCT/EP2016/080111 WO2017097845A1 (fr) 2015-12-08 2016-12-07 Composition pharmaceutique comprenant un inhibiteur puissant d'urat1

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021182955A Division JP2022033758A (ja) 2015-12-08 2021-11-10 生理活性の強い、ｕｒａｔ１のインヒビターを含む医薬組成物

Publications (2)

Publication Number Publication Date
JP2019501895A JP2019501895A (ja) 2019-01-24
JP6976946B2 true JP6976946B2 (ja) 2021-12-08

Family

ID=57517882

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018529601A Expired - Fee Related JP6976946B2 (ja) 2015-12-08 2016-12-07 生理活性の強い、ｕｒａｔ１のインヒビターを含む医薬組成物
JP2021182955A Pending JP2022033758A (ja) 2015-12-08 2021-11-10 生理活性の強い、ｕｒａｔ１のインヒビターを含む医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021182955A Pending JP2022033758A (ja) 2015-12-08 2021-11-10 生理活性の強い、ｕｒａｔ１のインヒビターを含む医薬組成物

Country Status (20)

Country Link
US (3) US20180360761A1 (fr)
EP (1) EP3386485A1 (fr)
JP (2) JP6976946B2 (fr)
KR (1) KR20180082613A (fr)
CN (1) CN108289848A (fr)
AU (1) AU2016368622B2 (fr)
BR (1) BR112018011376A2 (fr)
CA (1) CA3006167A1 (fr)
CL (1) CL2018001510A1 (fr)
CO (1) CO2018005842A2 (fr)
EA (1) EA038828B9 (fr)
HK (2) HK1253034A1 (fr)
IL (1) IL259844B (fr)
MA (1) MA43402A (fr)
MX (1) MX394588B (fr)
PE (1) PE20181521A1 (fr)
PH (1) PH12018501236A1 (fr)
SG (1) SG11201804100UA (fr)
WO (1) WO2017097845A1 (fr)
ZA (1) ZA201804519B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2704233T3 (es) * 2011-11-03 2019-03-15 Ardea Biosciences Inc Compuesto de piridina 3,4-di-sustituido, procedimientos de uso y composiciones que comprenden el mismo
TWI780270B (zh) * 2017-11-28 2022-10-11 靜岡縣公立大學法人 固體分散體
WO2020070539A1 (fr) * 2018-10-01 2020-04-09 Astrazeneca Ab Compositions pour réduire l'acide urique sérique
CN112057429B (zh) * 2019-06-11 2023-04-07 上海京新生物医药有限公司 雷西纳德控释药物组合物
PH12022550093A1 (en) * 2019-07-16 2022-11-21 Astrazeneca Ab Dose dumping resistant pharmaceutical compositions comprising verinurad
UY39094A (es) * 2020-02-27 2021-07-30 Hk Inno N Corp Composición farmacéutica que comprende compuesto derivado de bencimidazol
CN113368067A (zh) * 2020-07-23 2021-09-10 太阳升(亳州)生物医药科技有限公司 制备用于降低血液尿酸水平的口服药物片剂的方法
CN113368073A (zh) * 2020-07-23 2021-09-10 太阳升(亳州)生物医药科技有限公司 制备用于降低血液尿酸水平的药物制剂的方法
CN113368032A (zh) * 2020-07-23 2021-09-10 太阳升(亳州)生物医药科技有限公司 药物组合物、口服固体制剂及其制备方法和用途
WO2022162021A1 (fr) 2021-01-27 2022-08-04 Astrazeneca Ab Compositions de vérinurad et procédés d'utilisation
AR126164A1 (es) * 2021-06-17 2023-09-27 Lg Chemical Ltd Formulación compuesta para dosificación oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico
KR20240055886A (ko) * 2021-09-17 2024-04-29 하이노바 파마슈티컬스 인코포레이티드 퀴놀린계 화합물의 서방성 정제 및 그 제조 방법
JP7515533B2 (ja) * 2022-04-28 2024-07-12 沢井製薬株式会社 デスロラタジン含有フィルムコーティング錠剤
JP2025535716A (ja) * 2022-10-04 2025-10-28 エングレイル セラピューティクス，インコーポレーテッド Ｇａｂａａ受容体モジュレーターおよびその使用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2010416B2 (de) * 1970-03-05 1979-03-29 Hoechst Ag, 6000 Frankfurt Oral anwendbare Arzneiform mit Retardwirkung
JPH04234812A (ja) * 1990-03-16 1992-08-24 Yamanouchi Pharmaceut Co Ltd 持続性製剤用顆粒
JP2008530145A (ja) * 2005-02-15 2008-08-07 ワイス 経口投与可能なｃｃｉ−７７９製剤
DK1909766T3 (en) * 2005-07-28 2016-04-04 Shire Llc PHARMACEUTICAL FORMULATIONS / FORMATIONS OF guanfacine SUITABLE FOR DAILY ADMINISTRATION IN SINGLE DOSE FORM
US20090104266A1 (en) * 2005-09-15 2009-04-23 Tobias Jung 3-(2-dimethylaminomethylcy clohexyl)phenol retard formulation
EP2560642A4 (fr) * 2010-03-30 2013-12-18 Ardea Biosciences Inc Traitement de la goutte
ES2670700T3 (es) * 2010-06-15 2018-05-31 Ardea Biosciences, Inc. Tratamiento de gota e hiperuricemia
AR081930A1 (es) * 2010-06-16 2012-10-31 Ardea Biosciences Inc Compuestos de tioacetato
ES2704233T3 (es) * 2011-11-03 2019-03-15 Ardea Biosciences Inc Compuesto de piridina 3,4-di-sustituido, procedimientos de uso y composiciones que comprenden el mismo

Also Published As

Publication number Publication date
CN108289848A (zh) 2018-07-17
PH12018501236A1 (en) 2019-02-18
BR112018011376A2 (pt) 2018-12-04
MX394588B (es) 2025-03-24
US20230011269A1 (en) 2023-01-12
CA3006167A1 (fr) 2017-06-15
SG11201804100UA (en) 2018-06-28
IL259844A (en) 2018-07-31
MA43402A (fr) 2018-10-17
IL259844B (en) 2022-04-01
CO2018005842A2 (es) 2018-07-10
JP2019501895A (ja) 2019-01-24
PE20181521A1 (es) 2018-09-24
EA038828B1 (ru) 2021-10-26
MX2018006903A (es) 2018-11-09
HK1256256A1 (zh) 2019-09-20
KR20180082613A (ko) 2018-07-18
ZA201804519B (en) 2022-04-28
EA038828B9 (ru) 2021-12-03
AU2016368622B2 (en) 2022-09-08
US20180360761A1 (en) 2018-12-20
EP3386485A1 (fr) 2018-10-17
AU2016368622A1 (en) 2018-06-07
US20210113472A1 (en) 2021-04-22
CL2018001510A1 (es) 2018-09-21
HK1253034A1 (zh) 2019-06-06
WO2017097845A1 (fr) 2017-06-15
JP2022033758A (ja) 2022-03-02
EA201891267A1 (ru) 2019-01-31

Similar Documents

Publication Publication Date Title
JP2022033758A (ja) 生理活性の強い、ｕｒａｔ１のインヒビターを含む医薬組成物
TWI415635B (zh) 加衣錠片調製物及製備彼之方法
WO2019228363A1 (fr) Combinaison pharmaceutique, composition et préparation de composé contenant un activateur de glucokinase et un bloqueur de canal k-atp, son procédé de préparation et son utilisation
KR101238156B1 (ko) 약제학적 제제
EP2275093A2 (fr) Formulation pharmaceutique
CA2909370A1 (fr) Formulations de colchicine a liberation prolongee et procedes d'utilisation de ces dernieres
KR20090091084A (ko) 방출성이 제어된 약제학적 제제
WO2011098483A1 (fr) Compositions pharmaceutiques comprenant une combinaison de metformine et de sitagliptine
US20030224045A1 (en) Combination immediate release sustained release levodopa/carbidopa dosage forms
CN103417505A (zh) 具有双相释药行为的石杉碱甲控释制剂及其制备方法
KR20100059912A (ko) 알리스키렌 및 발사르탄의 제약 조합물
US20120003307A1 (en) Levetiracetam controlled release composition
JP2008534681A (ja) ジピリダモール持続放出製剤及びそれを調製のための方法
KR20090091075A (ko) 심혈관계 질환 치료용 약제학적 제제
CA3021066C (fr) Compositions pharmaceutiques orales de nicotinamide
CN105431140B (zh) 含有缓释二甲双胍和速释HMG-CoA还原酶抑制剂的复合制剂
US20130251793A1 (en) Pharmaceutical composition comprising phentermine and topiramate
KR20090107954A (ko) 약제학적 제제
KR20090107960A (ko) 심혈관계 질환 치료용 약제학적 제제
WO2025163673A1 (fr) Comprimés d'acamprosate de calcium résistants à la libération massive
HK40005191A (en) Oral pharmaceutical compositions of nicotinamide
HK40005191B (en) Oral pharmaceutical compositions of nicotinamide

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191120

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200806

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200811

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210511

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210730

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211012

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211110

R150 Certificate of patent or registration of utility model

Ref document number: 6976946

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees